{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:37:25Z","timestamp":1786361845899,"version":"build-2736575974"},"reference-count":9,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,7,31]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    Myeloproliferative neoplasms (MPNs) are broadly classified into\n                    <jats:italic>BCR::ABL1<\/jats:italic>\n                    -positive chronic myeloid leukaemia (CML) and\n                    <jats:italic>BCR::ABL1<\/jats:italic>\n                    -negative subtypes such as polycythaemia vera (PV), essential thrombocythaemia and primary myelofibrosis. Although traditionally considered mutually exclusive, rare cases of coexisting\n                    <jats:italic>BCR::ABL1<\/jats:italic>\n                    rearrangement and Janus kinase 2 (\n                    <jats:italic>JAK2<\/jats:italic>\n                    ) mutation have increasingly been recognised.\n                  <\/jats:p>\n                  <jats:p>\n                    We report the first Philippine case series of three patients with concurrent CML and\n                    <jats:italic>JAK2<\/jats:italic>\n                    -positive MPNs. Two patients developed PV 6\u20139 years after the initial diagnosis of CML despite ongoing tyrosine kinase inhibitor (TKI) therapy and molecular response, while a third patient had persistent thrombocytosis and was later found to have a concomitant\n                    <jats:italic>JAK2<\/jats:italic>\n                    -mutated MPN with fibrotic marrow features after 4 years.\n                  <\/jats:p>\n                  <jats:p>\n                    Compared with previously reported cases, our series demonstrates similarly delayed emergence of\n                    <jats:italic>JAK2<\/jats:italic>\n                    -mutated clones while highlighting real-world challenges in TKI intolerance, sequential TKI use and the need for combined cytoreductive strategies in a resource-limited setting.\n                  <\/jats:p>","DOI":"10.1136\/bcr-2025-271701","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:25:18Z","timestamp":1786361118000},"page":"e271701","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["First Philippine report of myeloproliferative neoplasms with concurrent\n                    <i>JAK2<\/i>\n                    and\n                    <i>BCR::ABL1<\/i>\n                    mutations"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9789-620X","authenticated-orcid":false,"suffix":"Jr","given":"Rene A","family":"Amadore","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Philippine General Hospital, Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowel David R","family":"Yap","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Philippine General Hospital, Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Kristine H","family":"Quero-Taggaoa","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Philippine General Hospital, Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"2026081004251188000_19.8.e271701.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"2026081004251188000_19.8.e271701.2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1329298","article-title":"Co-occurrence of JAK2-V617 F mutation and BCR::ABL1 translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination","volume":"13","author":"Zanelli","year":"2023","journal-title":"Front Oncol"},{"key":"2026081004251188000_19.8.e271701.3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4172\/2332-0672.1000116","article-title":"Detection of Jak2 V617f Mutation, Secondary to the Presence of Bcr-Abl1 Translocation in a Patient with Chronic Myeloid Leukemia: Report of a Case and Review of the Literature","volume":"02","author":"Damaris Tinti,","year":"2014","journal-title":"Int J Genomic Med"},{"key":"2026081004251188000_19.8.e271701.4","doi-asserted-by":"crossref","unstructured":"Bader G , Dreiling B . Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature. J Investig Med High Impact Case Rep 2019;7. doi:10.1177\/2324709619832322","DOI":"10.1177\/2324709619832322"},{"key":"2026081004251188000_19.8.e271701.5","first-page":"1001","article-title":"Concomitant presence of JAK2V617F mutation and BCR-ABL translocation in two patients: A new entity or a variant of myeloproliferative neoplasms (Case report)","volume":"18","author":"Mousinho","year":"2018","journal-title":"Mol Med Rep"},{"key":"2026081004251188000_19.8.e271701.6","first-page":"100151","article-title":"Concomitant JAK2 V617F mutation and rare e1a2 BCR-ABL1 transcript isoform in a patient with myeloproliferative neoplasm","volume":"6","author":"Soriani","year":"2022","journal-title":"Curr Probl Cancer Case Rep"},{"key":"2026081004251188000_19.8.e271701.7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/BS9.0000000000000129","article-title":"BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia","volume":"4","author":"Zhang","year":"2022","journal-title":"Blood Sci"},{"key":"2026081004251188000_19.8.e271701.8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5045\/br.2020.55.1.62","article-title":"Clinical significance of myeloproliferative neoplasms with JAK2V617F mutations and major BCR-ABL1 translocations: a literature review with case presentation","volume":"55","author":"Kim","year":"2020","journal-title":"Blood Res"},{"key":"2026081004251188000_19.8.e271701.9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12308-021-00458-4","article-title":"Sequential development of JAK2V617F and BCR-ABL1: a \u201cdouble-hit\u201d myeloproliferative neoplasm with morphologic transition","volume":"14","author":"Zhao","year":"2021","journal-title":"J Hematopathol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-271701","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:25:20Z","timestamp":1786361120000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-271701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":9,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,10]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/bcr-2025-271701"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-271701","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}